COVID-19 studies:  C19 studies: C19:  IvermectinIVM Vitamin DV.D HC QHC Q Vitamin CV.C ZincZn PVP-IPVP-I FLVFLV REGNR2 LY-CoVLY RemdesivirRMD
HCQ study #138 of 259
9/14 Late treatment study
Lauriola et al., Clinical and Translational Science, doi:10.1111/cts.12860 (Peer Reviewed)
Effect of combination therapy of hydroxychloroquine and azithromycin on mortality in COVID‐19 patients
Source   PDF   Share   Tweet
Retrospective 377 patients, 73% reduction in mortality with HCQ+AZ, adjusted hazard ratio HR 0.27 [0.17-0.41]. Mean age 71.8. No serious adverse events. Subject to incomplete adjustment for confounders.

Lauriola et al., 9/14/2020, retrospective, Italy, Europe, peer-reviewed, mean age 71.8, 10 authors.
risk of death, 73.5% lower, RR 0.27, p < 0.001, treatment 102 of 297 (34.3%), control 35 of 63 (55.6%), adjusted per study.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. For an individual study the most serious outcome may have a smaller number of events and lower statistical signficance, however this provides the strongest evidence for the most serious outcomes when combining the results of many trials.
Details of all 259 studies    Meta analysis
Please send us corrections, updates, or comments.
Submit